630 related articles for article (PubMed ID: 14519673)
1. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
4. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
Chen J; Li H; Li R; Bu D; Wan Z
J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients.
Dannaoui E; Meletiadis J; Tortorano AM; Symoens F; Nolard N; Viviani MA; Piens MA; Lebeau B; Verweij PE; Grillot R; And The Ebga Network
J Med Microbiol; 2004 Feb; 53(Pt 2):129-134. PubMed ID: 14729934
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
[TBL] [Abstract][Full Text] [Related]
9. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
11. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
[TBL] [Abstract][Full Text] [Related]
12. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
Te Dorsthorst DT; Mouton JW; van den Beukel CJ; van der Lee HA; Meis JF; Verweij PE
Antimicrob Agents Chemother; 2004 Aug; 48(8):3147-50. PubMed ID: 15273136
[TBL] [Abstract][Full Text] [Related]
13. Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.
Araujo R; Coutinho I; Espinel-Ingroff A
J Antimicrob Chemother; 2008 Dec; 62(6):1277-80. PubMed ID: 18824456
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
15. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
16. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.
Dannaoui E; Borel E; Persat F; Monier MF; Piens MA; Network E
J Med Microbiol; 1999 Dec; 48(12):1087-1093. PubMed ID: 10591162
[TBL] [Abstract][Full Text] [Related]
17. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
19. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
Gürcan S; Tikveşli M; Eryildiz C; Evci C; Ener B
Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
[TBL] [Abstract][Full Text] [Related]
20. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
